International law firm Simmons & Simmons has advised NetScientific plc on its placing of £30 million of new shares and admission to AIM.

International law firm Simmons & Simmons has advised NetScientific plc on its placing of £30 million of new shares and admission to AIM, which was completed today.

NetScientific is a healthcare medical technology company that identifies, develops and commercialises research and technologies originating from leading universities, teaching hospitals and research institutes globally, particularly in the United Kingdom and the United States.  The Group is primarily focused on identifying and developing research and technologies for use in five chronic disease areas within the healthcare diagnostics sector: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health. Liberum Capital Limited is NetScientific’s nominated adviser and broker.

The Simmons & Simmons team was led by Corporate partner and life sciences specialist Charles Mayo and Corporate associate Tara Waters. They were supported by Corporate partner Colin Bole, Intellectual property partner Richard Binns and associate David Swain, Employee incentives partner Ian Fraser and associate Richard Pilsworth, and Tax partner Nick Cronkshaw and associate Mark Watterson.

Commenting on the transaction, Charles Mayo, said: NetScientific’s strategy is to fund and develop technology that offers transformative benefits to people with chronic disease. We are very pleased and proud to use our life sciences sector-based expertise to support NetScientific on its IPO and with the implementation of its strategy.”

Farad Azima, NetScientific's CEO, said: "Simmons & Simmons’ sector expertise and service have been a real help to us in achieving this IPO. We’ve enjoyed working with Charles Mayo and his team, and really appreciated their support.”